These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23018529)

  • 1. Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis.
    Khadzhynov D; Slowinski T; Lieker I; Neumayer HH; Albrecht D; Streefkerk HJ; Rebello S; Peters H
    Clin Pharmacokinet; 2012 Oct; 51(10):661-9. PubMed ID: 23018529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study.
    Hu P; Bartlett M; Karan RS; Jiang J; Zhang S; Zhang J; Howard D; Yeh CM; Al-Fayoumi S; Jarugula V; Dole WP
    Clin Drug Investig; 2010; 30(4):221-8. PubMed ID: 20192280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.
    Vaidyanathan S; Bigler H; Yeh C; Bizot MN; Dieterich HA; Howard D; Dole WP
    Clin Pharmacokinet; 2007; 46(8):661-75. PubMed ID: 17655373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
    Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects.
    Limoges D; Dieterich HA; Yeh CM; Vaidyanathan S; Howard D; Dole WP
    Int J Clin Pharmacol Ther; 2008 May; 46(5):252-8. PubMed ID: 18538111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.
    Huang HL; Vaidyanathan S; Yeh CM; Bizot MN; Dieterich HA; Dole WP; Howard D
    Curr Med Res Opin; 2008 Sep; 24(9):2449-56. PubMed ID: 18662494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
    Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
    Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
    Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
    Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
    Yan JH; Jarugula V; Sabo R; Papst CC; Zhang J; Dole WP
    J Clin Pharmacol; 2012 May; 52(5):645-55. PubMed ID: 21659626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
    Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
    J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
    Sunzel M; Learoyd M; Li J; Li Y; Ngo N; Edeki T
    Int J Antimicrob Agents; 2015 Dec; 46(6):682-8. PubMed ID: 26545441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects.
    Vaidyanathan S; Jermany J; Yeh C; Bizot MN; Camisasca R
    Br J Clin Pharmacol; 2006 Dec; 62(6):690-8. PubMed ID: 17118124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects.
    Vaidyanathan S; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
    J Clin Pharmacol; 2007 Apr; 47(4):453-60. PubMed ID: 17389554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics and pharmacodynamics of aliskiren.
    Vaidyanathan S; Jarugula V; Dieterich HA; Howard D; Dole WP
    Clin Pharmacokinet; 2008; 47(8):515-31. PubMed ID: 18611061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
    Vaidyanathan S; Bartlett M; Dieterich HA; Yeh CM; Antunes A; Howard D; Dole WP
    Cardiovasc Ther; 2008; 26(4):238-46. PubMed ID: 19035874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
    Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
    Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
    Jordan J; Engeli S; Boye SW; Le Breton S; Keefe DL
    Hypertension; 2007 May; 49(5):1047-55. PubMed ID: 17353513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension.
    Sullivan JE; Keefe D; Zhou Y; Satlin L; Fang H; Yan JH
    Clin Pediatr (Phila); 2013 Jul; 52(7):599-607. PubMed ID: 23610239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.
    Buczko W; Hermanowicz JM
    Pharmacol Rep; 2008; 60(5):623-31. PubMed ID: 19066408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension.
    Gradman AH; Traub D
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S22-30. PubMed ID: 17401313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.